We are live on ! Find out more

NeuroSense Therapeutics

NRSN

Market cap $3.34M

1.76 USD

-0.22

11.11%

At close Updated Nov 11, 11:23 AM EST

1 day

-11.11%

5 days

17.33%

1 month

-49.43%

3 months

-81.45%

6 months

-89.46%

Year to date

-88.72%

1 year

-90.87%

5 years

-97.82%

10 years

-97.82%

About: NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease, and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.

Employees: 16

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 0%

Neutral 100%

Negative 0%

NeuroSense to Strengthen PrimeC Canadian ALS Submission With New NfL Data

Expanded package to include new neurofilament light chain (NfL) analysis; Health Canada confirms March 2027 filing timeline Submission would be PrimeC's first marketing application in any jurisdiction, potentially addressing approximately 4,000 Canadians living with ALS CAMBRIDGE, Mass., Nov. 2, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd.

NeuroSense to Strengthen PrimeC Canadian ALS Submission With New NfL Data

NeuroSense to Present Integrated Clinical and Biomarker Evidence Shaping PrimeC's Phase 3 Development at NEALS 2026

Presentation will highlight how findings from the PARADIGM program are informing the clinical development strategy for PARAGON CAMBRIDGE, Mass., Oct. 29, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd.

NeuroSense to Present Integrated Clinical and Biomarker Evidence Shaping PrimeC's Phase 3 Development at NEALS 2026

NeuroSense Files U.S. Patent Application for Traumatic Brain Injury

Patent application seeks protection for PrimeC use in concussion, blast-related brain injury and chronic traumatic encephalopathy (CTE) Positions PrimeC for potential expansion beyond ALS into an indication affecting millions worldwide, with no approved disease-modifying therapy Filing supports opportunities for research partnerships CAMBRIDGE, Mass., Oct. 19, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd.

NeuroSense Files U.S. Patent Application for Traumatic Brain Injury

NeuroSense Secures Nasdaq Hearing Date as PrimeC Approaches Key Regulatory and Funding Milestones

Shares continue to trade on Nasdaq pending the Panel's decision; minimum bid price compliance already regained Near-term catalysts include a New Drug Submission to Health Canada targeted for December 2026 and a decision on non-dilutive funding for the Phase 3 PARAGON trial expected in Q1 2027 CAMBRIDGE, Mass., Oct. 13, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd.

NeuroSense Secures Nasdaq Hearing Date as PrimeC Approaches Key Regulatory and Funding Milestones

NeuroSense Provides Update on Nasdaq Listing Compliance

Company regains compliance with Nasdaq's minimum bid price requirement and intends to request a Nasdaq Hearings Panel hearing to seek additional time to regain compliance with the minimum market value requirement CAMBRIDGE, Mass., Oct. 2, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd.

NeuroSense Provides Update on Nasdaq Listing Compliance

NeuroSense to Participate in the 5th Annual ROTH Healthcare Opportunities Conference

Management will participate in the 5th Annual ROTH Healthcare Opportunities Conference on September 29, 2026 and will be available for one-on-one investor meetings during the conference CAMBRIDGE, Mass., Sept. 28, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd.

NeuroSense to Participate in the 5th Annual ROTH Healthcare Opportunities Conference

NeuroSense Provides Business Update and Progress for the First Half of 2026

CAMBRIDGE, Mass., Sept. 25, 2026 /PRNewswire/ -- Therapeutics Ltd.

NeuroSense Provides Business Update and Progress for the First Half of 2026

NeuroSense to Present at H.C. Wainwright 28th Annual Global Investment Conference

Company presentation on Tuesday, September 15 at 4:30 p.m. ET Management will be available for one-on-one investor meetings during the conference CAMBRIDGE, Mass.

NeuroSense to Present at H.C. Wainwright 28th Annual Global Investment Conference

NeuroSense Unveils Accelerated, Capital-Efficient Strategy to Advance PrimeC Toward Potential Approval in ALS

Three-part program - AI-enabled characterization of PrimeC's formulation advantage, an active-comparator trial against edaravone, and a streamlined pivotal pathway - is designed to strengthen PrimeC's differentiation, shorten the time to potential commercialization, and significantly reduce overall development costs, complemented by a parallel regulatory pathway in Canada. CAMBRIDGE, Mass.

NeuroSense Unveils Accelerated, Capital-Efficient Strategy to Advance PrimeC Toward Potential Approval in ALS

NeuroSense Issues CEO Letter to Shareholders

CAMBRIDGE, Mass., Aug. 13, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd.

NeuroSense Issues CEO Letter to Shareholders

See News Rankings

Price charts implemented using Lightweight Charts™